Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP versus tranexamic acid for persistent post-acne facial erythema
IRCT20240822062839N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tranexamic acid and platelet-rich plasma in Postinflammatory erythema (PIE) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Reduction in post-acne erythema and Adverse events related to PRP or tranexamic acid. Started Sep 2025; status: completed.
02
Drugs
tranexamic acidplatelet-rich plasma
03
Conditions
Postinflammatory erythema (PIE)
Beyond the preview
Go deeper on IRCT20240822062839N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240822062839N2.